muraglitazar has been researched along with Diabetes Mellitus, Type 2 in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 25 (78.13) | 29.6817 |
| 2010's | 5 (15.63) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Henke, BR | 1 |
| Biller, SA; Cap, M; Chandrasena, G; Chang, SY; Chen, S; Cheng, L; Cheng, PT; Devasthale, PV; Doweyko, A; Farrelly, D; Golla, R; Grover, G; Hariharan, N; Harrity, T; Humphreys, WG; Jeon, Y; Ma, Z; Moore, L; Qu, F; Ren, J; Ryono, DE; Sasseville, VG; Seethala, R; Selan, F; Shao, C; Sleph, P; Sun, W; Tieman, A; Wang, W; Wetterau, JR; Zhang, H | 1 |
| Ahn, BN; Bae, MH; Chong, W; Han, T; Kim, E; Kim, EJ; Kim, JK; Kim, MK; Kim, SH; Lee, CH; Lim, JI; Moon, HS; Park, CS; Shim, HJ; Shin, CY; Shin, YA; Son, MH | 1 |
| Apedo, A; Cap, M; Chen, SS; Cheng, PT; Chu, C; Devasthale, P; Ding, CZ; Doweyko, AM; Farrelly, D; Flynn, N; Gu, L; Hariharan, N; Harrity, T; Herpin, T; Hosagrahara, V; Kadiyala, P; Kunselman, L; Lai, Z; Li, YX; Lippy, J; Locke, K; Morgan, N; Morton, G; O'Malley, K; Qu, F; Ryono, D; Smirk, R; Wang, T; Wang, W; Wu, S; Xu, C; Ye, XX; Zahler, R; Zhang, H; Zhang, L | 1 |
| Califf, RM; Demets, D; George, JT; Gerstein, HC; Granger, C; Green, JB; Hobbs, T; Holman, RR; Lawson, FC; Leiter, LA; McGuire, DK; McMurray, J; Pagidipati, NJ; Pfeffer, MA; Reusch, J; Riesmeyer, JS; Roe, MT; Rosenberg, Y; Sharma, A; Temple, R; Wiviott, S | 1 |
| Drosatos, K; Kalliora, C | 1 |
| Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH | 1 |
| Cersosimo, E; Coletta, DK; DeFronzo, RA; Fernandez, M; Gastaldelli, A; Musi, N | 1 |
| Fiedorek, FT; Ledeine, JM; Rubin, CJ | 1 |
| Achanzar, W; Cheng, P; Cosma, G; Delmonte, T; Dracopoli, NC; Geese, WJ; Hariharan, N; Hui, L; Krishnan, B; Ordway, N; Ranade, K; Rubin, C; Tomlinson, L | 1 |
| Charbonnel, B | 1 |
| De Pril, V; Fiedorek, FT; Rubin, CJ | 1 |
| Fiedorek, FT; Rubin, CJ; Viraswami-Appanna, K | 1 |
| Casolaro, A; Cersosimo, E; DeFronzo, RA; Fernandez, M; Ferrannini, E; Gastaldelli, A; Hardies, J; Musi, N; Petz, R; Tantiwong, P; Triplitt, C | 1 |
| Amacher, DE; Boucher, GG; Francone, O; Kerlin, RL; Morton, D; Pettersen, JC; Pruimboom-Brees, IM; Will, Y | 1 |
| Buse, JB; Davidson, JA; Frederich, R; Lin, KC; Montoro, R; Rubin, CJ; Shockey, G; Viraswami-Appanna, K | 1 |
| Nissen, SE; Topol, EJ; Wolski, K | 1 |
| Brophy, JM | 1 |
| Kordella, T | 1 |
| Cox, SL | 1 |
| Biller, S; Cap, M; Chen, S; Cheng, PT; Chu, C; Devasthale, P; Farrelly, D; Fenderson, W; Gregg, R; Gu, L; Hariharan, N; Harrity, T; Jeon, Y; Kunselman, L; Mookhtiar, KA; Ponticiello, R; Qu, F; Ren, J; Ryono, D; Seethala, R; Shao, C; Tieman, A; Wang, W; Wetterau, J; Yang, WP; Zhang, H; Zhou, M | 1 |
| Lebovitz, H | 1 |
| Heinzl, S | 1 |
| Liebson, PR | 1 |
| Belder, R; DeFronzo, RA; Fiedorek, FT; Gross, J; Kendall, DM; Ledeine, JM; Mohideen, P; Norwood, P; O'Mahony, M; Roberts, A; Rubin, CJ; Sall, K; Sloan, G | 1 |
| Beckey, C; Parra, D; Thomas, T | 1 |
| Najman, DM | 1 |
| Doggrell, SA | 1 |
| Fiévet, C; Fruchart, JC; Staels, B | 1 |
8 review(s) available for muraglitazar and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.
Topics: Alkanesulfonates; Animals; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energy Metabolism; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Signal Transduction; Thiophenes | 2020 |
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Oxazoles; Pancreatic Neoplasms; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2014 |
Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.
Topics: Adult; Aged; Animals; Area Under Curve; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Glycated Hemoglobin; Glycine; Half-Life; Humans; Hypoglycemic Agents; Male; Oxazoles; Peroxisome Proliferator-Activated Receptors; Tissue Distribution | 2005 |
Diabetes: assessing the pipeline.
Topics: Adamantane; Alkanesulfonates; Amyloid; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exenatide; Glycine; Humans; Hypoglycemic Agents; Indoles; Islet Amyloid Polypeptide; Maleimides; Nitriles; Oxazoles; Peptides; Phenylpropionates; Piperidines; PPAR alpha; PPAR gamma; Protein Kinase C; Pyrazoles; Pyrrolidines; Receptor, Cannabinoid, CB1; Receptors, Glucagon; Rimonabant; Venoms; Vildagliptin | 2006 |
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glycine; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Oxazoles; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
Muraglitazar and the FDA: what constitutes drug safety?
Topics: Animals; Blood Glucose; Databases, Factual; Diabetes Mellitus, Type 2; Drug Approval; Glycine; Humans; Oxazoles; Peroxisome Proliferator-Activated Receptors; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2006 |
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Topics: Alkanesulfonates; Animals; Diabetes Mellitus, Type 2; Glycine; Humans; Metabolic Syndrome; Models, Biological; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma | 2006 |
8 trial(s) available for muraglitazar and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.
Topics: Adiponectin; AMP-Activated Protein Kinases; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glycine; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Oxazoles; Oxidation-Reduction; PPAR alpha; PPAR gamma; Signal Transduction; Triglycerides | 2015 |
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Male; Metformin; Middle Aged; Oxazoles; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2008 |
Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
Topics: Animals; Diabetes Mellitus, Type 2; Edema; Endothelin-1; Female; Gene Expression Regulation; Glycine; Humans; Macaca fascicularis; Male; Oxazoles; Pharmacogenetics; Polymorphism, Single Nucleotide; PPAR gamma; Regression Analysis; Renin | 2008 |
Coadministration of muraglitazar plus glyburide: improvement of glycaemic and lipid profiles in patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Time Factors; Treatment Outcome | 2009 |
Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Edema; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Time Factors; Treatment Outcome; Weight Gain | 2009 |
Metabolic effects of muraglitazar in type 2 diabetic subjects.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Intra-Abdominal Fat; Male; Middle Aged; Oxazoles; Peroxisome Proliferator-Activated Receptors | 2011 |
Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Oxazoles; Peroxisome Proliferator-Activated Receptors | 2005 |
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A
Topics: Adult; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycine; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2006 |
16 other study(ies) available for muraglitazar and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and
Topics: Adipocytes; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids; Glycine; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Obese; Oxazoles; PPAR alpha; PPAR gamma; Transcriptional Activation; Triglycerides | 2005 |
Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists.
Topics: Animals; Combinatorial Chemistry Techniques; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Mice; Molecular Structure; PPAR alpha; PPAR gamma; Pyridines; Rats; Rats, Sprague-Dawley | 2008 |
Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Design; Female; Hypoglycemic Agents; Ligands; Mice; Mice, Obese; PPAR alpha; PPAR gamma; Pyrrolidines; Stereoisomerism; Structure-Activity Relationship; Triglycerides | 2015 |
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucose; Glycated Hemoglobin; Glycine; Government Regulation; Humans; Hypoglycemic Agents; Oxazoles; Phenylbutazone; Practice Guidelines as Topic; Risk; Rosiglitazone; Tolbutamide; United States; United States Food and Drug Administration | 2020 |
PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
Topics: Alkanesulfonates; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Thiophenes | 2009 |
The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; DNA Damage; Glycine; Hypoglycemic Agents; Ion Channels; Mice; Mitochondria; Mitochondrial Proteins; Oxazoles; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR alpha; PPAR gamma; Rats; RNA-Binding Proteins; Rodentia; Rosiglitazone; Sarcoma; Thermogenesis; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 1 | 2012 |
Molecule of the month. Muraglitazar.
Topics: Diabetes Mellitus, Type 2; Glycine; Humans; Oxazoles; PPAR alpha; PPAR gamma | 2005 |
Meeting highlights. 65th annual scientific sessions of the American Diabetes Association, San Diego. Dual PPAR agonist improves glycemic control, lipids in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Metabolic Syndrome; Oxazoles; Pioglitazone; Thiazolidinediones; United States | 2005 |
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Approval; Glycine; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Risk; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Selling safety--lessons from muraglitazar.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Glycine; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Risk; United States; United States Food and Drug Administration | 2005 |
One pill, two conditions.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycine; Humans; Hypercholesterolemia; Oxazoles; United States | 2005 |
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Corticosterone; Diabetes Mellitus, Type 2; Diet; Female; Glycine; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liver; Mice; Obesity; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2006 |
Adverse events related to muraglitazar use in diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Interactions; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones | 2006 |
Adverse events related to muraglitazar use in diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Interactions; Glycine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Oxazoles; PPAR alpha; PPAR gamma | 2006 |
Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Middle Aged; Oxazoles; Randomized Controlled Trials as Topic; Research Design; Weight Gain | 2006 |
A bumpy road to breakthroughs. The news: it's hard to beat today's cardiac treatments.
Topics: Animals; Atherosclerosis; Coronary Thrombosis; Diabetes Mellitus, Type 2; Ethics, Clinical; Glycine; Heart Failure; Humans; Indoleacetic Acids; Myocardial Infarction; Oxazoles; Prostheses and Implants; Stroke; Treatment Failure; Ultrasonography | 2006 |